Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Alarcon

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
Transplantation and Cellular Therapy|November 7, 2022
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell LymphomaShalev Fried, Roni Shouval, Moneeza Walji, et al.
Transplantation and Cellular Therapy|January 1, 2023
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell TherapyHarper Hubbeling, Emily A Silverman, Laure Michaud, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
Blood Advances|July 31, 2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphomaMichael Scordo, Jessica R Flynn, Mithat Gonen, et al.
Blood Advances|June 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomasGustav Y Cederquist, Javin Schefflein, Sean M Devlin, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Transplantation and Cellular Therapy|August 9, 2022
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell LymphomaKarthik Nath, Ana Alarcon Tomas, Jessica Flynn, et al.
Blood Cancer Journal|April 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphomaAlejandro Luna, Sean M Devlin, Kai Rejeski, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
Transplantation and Cellular Therapy|November 7, 2022
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell LymphomaShalev Fried, Roni Shouval, Moneeza Walji, et al.
Transplantation and Cellular Therapy|January 1, 2023
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell TherapyHarper Hubbeling, Emily A Silverman, Laure Michaud, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
Blood Advances|July 31, 2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphomaMichael Scordo, Jessica R Flynn, Mithat Gonen, et al.
Blood Advances|June 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomasGustav Y Cederquist, Javin Schefflein, Sean M Devlin, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Transplantation and Cellular Therapy|August 9, 2022
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell LymphomaKarthik Nath, Ana Alarcon Tomas, Jessica Flynn, et al.
Blood Cancer Journal|April 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphomaAlejandro Luna, Sean M Devlin, Kai Rejeski, et al.
Pageof 6